US-based Zhittya Genesis Medicine Inc, a company advancing a group of drugs that trigger the human body's natural regeneration process, has received official regulatory approval from COFEPRIS, the Mexican governing body, to test its novel biological drug in patients with Parkinson's disease, it was reported on Tuesday.

Zambrano Hospital in Monterrey, Mexico, will be conducting the phase one clinical study.

Three ascending doses of Zhittya's biological drug will be tested in patients with 'mild' to 'moderately severe' Parkinson's disease. There will be no placebo dose administered in this First in Man proof of concept study. While the primary purpose of this first clinical trial is to test for the safety of the drug, readouts on possible improvements in the patient's Parkinson disease symptoms will also be studied.